Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etaqualone SCHEMBL29357362 | 1.00 | ALDH1A1 (0.73) | ALDH1A1L3MBTL1LMNAHDAC1HDAC2 | |
| Etaqualone SCHEMBL30726094 | 1.00 | ALDH1A1 (0.73) | ALDH1A1L3MBTL1LMNAHDAC1HDAC2 | |
| Etaqualone SCHEMBL30726099 | 1.00 | ALDH1A1 (0.73) | ALDH1A1L3MBTL1LMNAHDAC1HDAC2 | |
| Methaqualone SCHEMBL29355239 | 0.84 | ALDH1A1 (1.00) | ALDH1A1L3MBTL1LMNATSHRGLA | |
| Methaqualone SCHEMBL29386732 | 0.84 | ALDH1A1 (1.00) | ALDH1A1L3MBTL1LMNATSHRGLA | |
| Methaqualone SCHEMBL20471677 | 0.84 | ALDH1A1 (1.00) | ALDH1A1L3MBTL1LMNATSHRGLA | |
| Methaqualone SCHEMBL43892 | 0.84 | ALDH1A1 (1.00) | ALDH1A1L3MBTL1LMNATSHRGLA | |
| SCHEMBL1129120 | 0.84 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1LMNAHDAC1HDAC2 | |
| SCHEMBL16596956 | 0.83 | L3MBTL1 (0.77) | ALDH1A1L3MBTL1LMNATSHRGLA | |
| Methaqualone SCHEMBL3500629 | 0.83 | ALDH1A1 (0.97) | ALDH1A1L3MBTL1LMNATSHRGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 569 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-12377065-B2 | Compositions for treatment of substance use disorder | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2025-08-05 | — | — | US | claimed |
| EP-4275752-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2023-11-15 | — | — | EP | claimed |
| US-20220233479-A1 | COMPOSITIONS FOR TREATMENT OF SUBSTANCE USE DISORDER | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2022-07-28 | — | — | US | claimed |
| US-20220072311-A1 | TREATMENT OF ADDICTION AND DEPENDENCY | TACA JR ARTURO C (US) | 2022-03-10 | — | — | US | claimed |
| US-11207322-B2 | Method and composition related to combination therapy for addiction | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-12-28 | — | — | US | claimed |
| WO-2021016637-A1 | COMPOSITIONS FOR TREATMENT OF SUBSTANCE USE DISORDER | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2021-01-28 | — | — | WO | claimed |
| US-20200188396-A1 | METHOD AND COMPOSITION RELATED TO COMBINATION THERAPY FOR ADDICTION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2020-06-18 | — | — | US | claimed |
| CN-106472231-B | Method for introducing and domesticating paphiopedilum armeniacum in south China | 中国科学院华南植物园 | 2020-04-21 | — | — | CN | claimed |
| WO-2020006606-A1 | A PHARMACEUTICAL COMPOSITION AND METHOD OF USE OF SAME | HELIUM 3 RESOURCES PTY LTD (AU) | 2020-01-09 | — | — | WO | claimed |
| US-20080066739-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20030062042-A1 | Aerosol generating method and device | ALEXZA PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | claimed |
| US-20030051728-A1 | Method and device for delivering a physiologically active compound | ALEXZA PHARMACEUTICALS, INC. | 2003-03-20 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-4557934-A | ALONG WITH A DIOL PYRROLIDONE OR AN AZACYCLOPENTAN-2-ONE | THE PROCTER & GAMBLE COMPANY (US) | 1985-12-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220233479-A1 | COMPOSITIONS FOR TREATMENT OF SUBSTANCE USE DISORDER | PNMT, METTL3, BHMT2 | ALDH1A1 236/4885L3MBTL1 1475/4885LMNA 2913/4885 |
| US-12377065-B2 | Compositions for treatment of substance use disorder | PNMT, METTL3, BHMT2 | ALDH1A1 236/4885L3MBTL1 1475/4885LMNA 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.